Analyst Call of the Year: Collins Stewart on Encysive (ENCY)
More News related to ALTH
- Allos Therapeutics to Present at the 8th Annual Needham Life Sciences Conference
- Allos Therapeutics (ALTH) Updates Phase 2 PROPEL Study At ASCO
- Allos Therapeutics Reports Updated Data from Pivotol Phase 2 PROPEL Study of Pralatrexate at 45th ASCO Annual Meeting
- Allos Therapeutics (ALTH) Announces FDA Accepts Pralatrexate NDA for Filing and Grants the Application Priority Review Status
- Allos Therapeutics Announces FDA Accepts Pralatrexate NDA for Filing and Grants the Application Priority Review Status
More News related to ARRY
- Boenning & Scattergood Initiates Coverage on Array BioPharma (ARRY)
- Array BioPharma to Present at the Jefferies 3rd Annual Healthcare Conference
- Array BioPharma Recognized by CIO Magazine as One of the CIO 100 Award Honorees
- Barclays Gets Bullish On US Biotechnology Sector (BBH)
- Array BioPharma (ARRY) Receives Additional $40 Million Funding Commitment From Deerfield Management
More News related to CYCC
- Unusual 11 Mid-Day Movers 6/15: JAZZ, AIM, QEPC, CYCC Higher; ODC, LEA, CDII, IRE Lower
- Cyclacel to Present At Annual Needham Biotechnology and Medical Technology Conference
- Sapacitabine Has Anti-Cancer Activity in Combination With Targeted Agents and Other Nucleoside Analogs
- Cyclacel Pharmaceuticals (CYCCP) Announces Positive Interim Data From Phase 2 Trials of Oral Seliciclib
- Cyclacel Reports Initial Phase 2 Seliciclib Data in Patients With Nasopharyngeal Carcinoma At 2009 ASCO Annual Meeting
Normally, Wall Street analysts get beat up in the media for their bad calls. So today we wanted to highlight an outstanding call by an analyst.
The stock: Encysive Pharmaceuticals Inc. (Nasdaq: ENCY).
The analyst: Andrew Fein at Collins Stewart
Yesterday, Fein upgraded Encysive to Buy. Today, the company announced a deal to be acquired by Pfizer (NYSE: PFE) for $2.35 per share, a huge premium to yesterday's $1.08 close. If you followed Fein's advice and bought the stock yesterday before the close you would be up over 100% today. Friday's close was $0.85, so if you bought yesterday morning, after the call, you would be up even more.
Fein was positive on Encysive's pulmonary hypertension drug THELIN in the EU and potential US approval. Pfizer saw the same thing and jumped at the chance to buy the entire company.
Great Call!
Some other pharmaceutical stocks Fein has Buy ratings on: Inspire Pharmaceuticals, Inc. (Nasdaq: ISPH), United Therapeutics Corp. (Nasdaq: UTHR), Array BioPharma, Inc. (Nasdaq: ARRY), GTC Biotherapeutics, Inc. (Nasdaq: GTCB), OSI Pharmaceuticals Inc. (Nasdaq: OSIP), Tercica Inc. (Nasdaq: TRCA), Metabasis Therapeutics Inc. (Nasdaq: MBRX), Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC), Rosetta Genomics, Ltd. (Nasdaq: ROSG), Insmed Incorporated (Nasdaq: INSM), Hana Biosciences Inc. (Nasdaq: HNAB), Allos Therapeutics, Inc. (Nasdaq: ALTH), Sunesis Pharmaceuticals Inc. (Nasdaq: SNSS).
Related Categories
Insiders' BlogTrader Talk
Stocks Mentioned
-0.27
+0.00Related Entities
Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
INSM
Dan Gillespie on Feb 20, 2008 03:42 PMA $3.00 dollar stock trading below a $1.00.